Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer's disease not affected by co-administration of memantine: An open-label, crossover, single-centre study

Clinical Drug Investigation

Volumn 28, Issue 6, 2008, Pages 361-374

  Shua Haim, Joshua ^a   Smith, Juanita ^a   Picard, Franck ^b   Sedek, Greg ^b   Athalye, Sandeep ^b   Pommier, Françoise ^c   Lefèvre, Gilbert ^b  

^a JERSEY SHORE UNIVERSITY MEDICAL CENTER   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c NOVARTIS PHARMA K K   (Japan)

Author keywords

Alzheimer's disease; Antidementias, pharmacokinetics; Cholinesterase inhibitors, pharmacokinetics; Memantine, pharmacokinetics; Rivastigmine, pharmacokinetics

Indexed keywords

DRUG METABOLITE; MEMANTINE; NAP 226 90; RIVASTIGMINE;

ADULT; AGED; AGITATION; ALZHEIMER DISEASE; ANXIETY; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DELUSION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; FALLING; FEMALE; GAIT DISORDER; HEADACHE; HUMAN; HYPERHIDROSIS; LIMB PAIN; MALAISE; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MORNING DOSAGE; NAUSEA; NECK PAIN; OPEN STUDY; POLLAKISURIA; PRIORITY JOURNAL; RESTLESSNESS; SIDE EFFECT; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY TRACT INFECTION; VOMITING;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AREA UNDER CURVE; BENZYLAMINES; CHOLINESTERASE INHIBITORS; CROSS-OVER STUDIES; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; MALE; MEMANTINE; MIDDLE AGED; PHENOLS; PHENYLCARBAMATES;

EID: 43649099862     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200828060-00004     Document Type: Article

References (38)

1. Alzheimer's Disease Management Council Clinical Consensus Panel. Alzheimer's disease: risk stratification, patient evaluation, and outcome-effective pharmacologic therapy. Year 2004 clinical update [online]. Thomson American Health Consultants. Available from URL: http://www.ahcpub.com [Accessed 2005 Jun 9]
2. American Psychiatric Association. Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life. Am J Psychiatry 1997; 154: 1-39
3. Cummings JL, Frank JC, Cherry D, et al. Guidelines for manag- ing Alzheimer's disease. Part I: assessment. Am Fam Physician 2002; 65: 2263-72
4. Cummings JL, Frank JC, Cherry D, et al. Guidelines for managing Alzheimer's disease. Part II: treatment. Am Fam Physician 2002; 65: 2525-34
5. Doody RS, Stevens JC, Beck RN, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56: 1154-66
6. Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA 1997; 278: 1363-71
7. Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer's disease: results from a multinational trial. Dement Geriatr Cogn Disord 1999; 10: 237-44
8. Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001; 57: 481-8
9. Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000; 54: 2261-8
10. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50: 136-45
11. Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000; 54: 2269-76
12. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. BMJ 2000; 321: 1-7
13. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57: 489-95
14. Farlow M, Anand R, Messina Jr J, et al. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol 2000; 44: 236-41
15. Karaman Y, Erdogan F, Koseoglu E, et al. A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease. Dement Geriatr Cogn Disord 2005; 19: 51-6
16. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999; 318: 633-8
17. Bullock R. The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis. Int J Clin Pract 2002; 56: 206-14
18. Ballard CG. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition. Eur Neurol 2002; 47: 64-70
19. Bentue-Ferrer D, Tribut O, Polard E, et al. Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists. CNS Drugs 2003; 17: 947-63
20. Grossberg GT, Stahelin HB, Messina JC, et al. Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications. Int J Geriatr Psychiatry 2000; 15: 242-7
21. Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 2002; 41: 719-39
22. Areosa SA, Sherriff F, McShane R. Memantine for dementia. Cochrane Database Syst Rev 2005 (3): CD003154
23. Lipton SA. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism. Curr Alzheimer Res 2005; 2: 155-65
24. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291: 317-24
25. Hartmann S, Mobius HJ. Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy. Int Clin Psychopharmacol 2003; 18: 81-5
26. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98
27. Diagnostic and statistical manual of mental disorders, 4th edition. Washington, DC: American Psychiatric Association, 1994
28. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-44
29. Pommier F, Frigola R. Quantitative determination of rivastigmine and its major metabolite in human plasma by liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 784: 301-13
30. Cutler NR, Polinsky RJ, Sramek JJ, et al. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease. Acta Neurol Scand 1998; 97: 244-50
31. Gobburu JV, Tammara V, Lesko L, et al. Pharmacokinetic-pharmacodynamic modeling of rivastigmine, a cholinesterase inhibitor, in patients with Alzheimer's disease. J Clin Pharmacol 2001; 41: 1082-90
32. Enz A, Gentsch C. Co-administration of memantine has no effect on the in vitro or ex vivo determined acetylcholinesterase inhibition of rivastigmine in the rat brain. Neuro-pharmacology 2004; 47: 408-13
33. Namenda [package insert]. St Louis (MO): Forest Laboratories, 2003
34. Periclou AP, Ventura D, Sherman T, et al. Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil. Ann Pharmacother 2004; 38: 1389-94
35. Yao C, Raoufinia A, Gold M, et al. Steady-state pharmacokinetics of galantamine are not affected by addition of meman-tine in healthy subjects. J Clin Pharmacol 2005; 45: 519-28
36. Hossain M, Jhee SS, Shiovitz T, et al. Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type. Clin Pharmacokinet 2002; 41: 225-34
37. Polinsky RJ. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther 1998; 20: 634-47
38. Jarvis B, Figgitt DP. Memantine. Drugs Aging 2003; 20: 465-76